文献速递头颈外科

监测中性粒细胞与淋巴细胞比值可能有助于预测纳武利尤单抗治疗复发或转移性头颈癌的抗癌效果

Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer.
PubMed 文献 · Head Neck · 2019-03-05

该回顾性分析纳入41例接受纳武利尤单抗治疗的复发或转移性头颈鳞状细胞癌患者,计算治疗前至治疗结束的中性粒细胞与淋巴细胞比值(NLR)。结果示前3个月内17例进展患者中13例(76%)治疗后NLR高于治疗前,而随访期间11例疾病稳定或部分缓解患者中10例(91%)治疗后NLR低于治疗前。结论提示监测NLR可能有助于更早确认纳武利尤单抗单药治疗失败。

要点

  • 前3个月内进展的17例患者中13例(76%)治疗后NLR高于治疗前。
  • 随访期间疾病稳定或部分缓解的11例患者中10例(91%)治疗后NLR低于治疗前。
  • 监测NLR可能有助于更早确认纳武利尤单抗单药治疗失败。

核心结论

  • 监测NLR可能有助于更早确认复发或转移性头颈鳞状细胞癌患者在接受纳武利尤单抗单药治疗期间的治疗失败。

研究设计与样本

  • 回顾性分析41例接受纳武利尤单抗治疗的复发或转移性头颈鳞状细胞癌患者。
  • 利用治疗前血液检查结果计算NLR,并持续至治疗结束。

主要发现

  • 前3个月内进展的17例患者中,13例(76%)治疗后NLR高于治疗前。
  • 随访期间疾病稳定或部分缓解的11例患者中,10例(91%)治疗后NLR低于治疗前。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil-to-lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab. PATIENTS AND METHODS: Forty-one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment. RESULTS: The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow-up period. CONCLUSION: Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Yasumatsu R, Wakasaki T, Hashimoto K, et al. Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer. Head Neck. 2019. PMID: 30835919. doi:10.1002/hed.25737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。